 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 | | 1996 | 4 | 1 | 5 | | 1997 | 3 | 4 | 7 | | 1998 | 9 | 4 | 13 | | 1999 | 10 | 5 | 15 | | 2000 | 9 | 6 | 15 | | 2001 | 5 | 7 | 12 | | 2002 | 18 | 9 | 27 | | 2003 | 16 | 9 | 25 | | 2004 | 19 | 8 | 27 | | 2005 | 22 | 10 | 32 | | 2006 | 30 | 8 | 38 | | 2007 | 47 | 13 | 60 | | 2008 | 39 | 18 | 57 | | 2009 | 41 | 23 | 64 | | 2010 | 36 | 16 | 52 | | 2011 | 54 | 17 | 71 | | 2012 | 44 | 25 | 69 | | 2013 | 51 | 28 | 79 | | 2014 | 54 | 23 | 77 | | 2015 | 63 | 24 | 87 | | 2016 | 63 | 42 | 105 | | 2017 | 60 | 31 | 91 | | 2018 | 60 | 22 | 82 | | 2019 | 49 | 19 | 68 | | 2020 | 44 | 12 | 56 | | 2021 | 41 | 3 | 44 | | 2022 | 27 | 4 | 31 | | 2023 | 31 | 0 | 31 | | 2024 | 25 | 22 | 47 | | 2025 | 28 | 5 | 33 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Strong Caldwell A, Milner DC, Mehta NB, Marin AI, Gill ZS, Manoharan N. MERTK INHIBITOR-ASSOCIATED RETINAL TOXICITY IN A HUMAN. Retin Cases Brief Rep. 2025 Nov 01; 19(6):807-810.
-
Canavan ME, Cheng L, Xiang JJ, Lin JK, Hui D, Zhao H, Nortje N, Ratan R, Cherny N, Pham T, Giordano SH, Niu J, Adelson KB. Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality. J Clin Oncol. 2025 Nov; 43(31):3391-3402.
-
Nishida-Aoki N, Zhu S, Chan M, Kang Y, Fujita M, Jiang X, McCabe M, Vaz JM, Davidson NE, Ghajar CM, Hansen K, Welm AL, Pillarisetty VG, Gujral TS. Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. Cell Rep Med. 2025 Oct 21; 6(10):102357.
-
Guo Y, Li Z, Parsels LA, Wang Z, Parsels JD, Dalvi A, The S, Hu N, Valvo VM, Doherty R, Peterson E, Wang X, Venkataraman S, Agnihotri S, Venneti S, Wahl DR, Green MD, Lawrence TS, Koschmann C, Morgan MA, Zhang Q. H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition. Neuro Oncol. 2025 Sep 17; 27(8):2129-2146.
-
Lachowiez CA, Heiblig M, Aspas Requena G, Tavernier-Tardy E, Dai F, Ashango AB, Peters DT, Fang J, Kaempf A, Long N, Eide CA, Kurtz SE, Xie W, Agarwal A, Sahasrabudhe A, McMahon CM, Amaya ML, Meyers G, Gandhi A, Leonard J, Hayes-Lattin B, Maziarz RT, Traer E, Cook RJ, Swords R, Braun TP, Saultz JN, Eckel AM, Loken MR, Zeidner JF, Tyner JW, Pollyea DA. Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study. Blood Cancer Discov. 2025 Sep 03; 6(5):437-449.
-
Murray AM, Swingle KL, Mitchell MJ. Engineering Nanoparticles for Gynecologic Cancer Therapy. ACS Nano. 2025 Sep 02; 19(34):30758-30785.
-
Olson J, Adamson L, Lang C, Miller K, Phillips E, Legette F, Loresto FL. Effects of Weighted Blankets on Anxiety for Pediatric Oncology Patients During Outpatient Chemotherapy Infusions. J Pediatr Hematol Oncol Nurs. 2025 May-Jun; 42(3):129-137.
-
Pearson AD, Chi S, Laetscht TW, Marshall L, Raetz E, George RE, Chesler L, Karres D, Scobie N, Knoderer H, Weigel B, Teachey D, Sonke GS, Seibel N, Pappo A, Nysom K, Muscal J, Molenaar J, McDonough J, Macy ME, Ludwinski D, Lin C, Ligas F, Lesa G, Knox L, Kirschbaum M, Kieran M, Kholmanskikh O, Jacobson A, Heenen D, Hawkins DS, Glade Bender J, Fox E, Demolis P, de Rojas T, Cox MC, Chauvin B, Blanc P, Vassal G. Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration. Eur J Cancer. 2025 Aug 26; 226:115629.
-
Lee JG, Petraccione J, Trese KA, Hughes AC, Ausec TR, Salzmann-Sullivan M, Su LJ, Kim MT, Roh S, Goodwin AP, Feng FX, Flaig TW, Shields CW. Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers. Adv Mater. 2025 Sep; 37(38):e2505231.
-
Gomes N, Frederick B, Tentler J, Su TT. Sensitivity to an inhibitor of translation elongation in solid and hematologic cancers. Sci Rep. 2025 Jul 01; 15(1):21328.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|